[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"deep-venous-thrombosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:deep-venous-thrombosis":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,46,80,104,139,163],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100493189","defiance-rct-of-clottriever-system-versus-anticoagulation-in-deep-vein-thrombosis-100493189",false,"NCT05701917","DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis","DEFIANCE - ClotTriever® Thrombectomy System vs. Anticoagulation Alone for Treatment of Deep Vein Thrombosis","DEFIANCE","Inclusion Criteria\n\n* Age ≥ 18 years\n* Proximal lower extremity unilateral DVT involving at least the common femoral, external iliac, or common iliac veins, alone or in combination\n* Symptom onset within 12 weeks of enrollment in the study\n* Significant symptoms, as defined by a Villalta score \\> 9\n* Willing and able to provide informed consent\n\nExclusion Criteria\n\n* Bilateral iliofemoral DVT\n* Prior venous stent in the target venous segment\n* IVC aplasia\u002Fhypoplasia or other congenital anatomic anomalies of the IVC or iliac veins\n* IVC filter in place at the time of enrollment\n* Limb-threatening circulatory compromise (e.g., phlegmasia)\n* Clot in transit including IVC thrombus presenting as extension of \\>2cm into the IVC from the CIV\n* Symptomatic PE with right heart strain where the physician judges that a DVT intervention is inappropriate at this time.\n* Inability to be a candidate for intervention due to medical or technical reasons based on physician judgement\n* Severe allergy, hypersensitivity to, or thrombocytopenia from heparin\n* Severe allergy to iodinated contrast agents that cannot be mitigated\n* Hemoglobin \\\u003C 8.0 g\u002FdL, INR \\> 1.7 before warfarin was started, or platelets \\\u003C 50,000\u002Fµl which cannot be corrected prior to enrollment\n* Severe renal impairment (estimated GFR \\\u003C 30 ml\u002Fmin) in patients who are not yet on dialysis\n* Inability to provide therapeutic anticoagulation per Investigator discretion\n* Uncontrolled severe hypertension on repeated readings (systolic \\> 180mmHg or diastolic \\> 105mmHg)\n* Recently (\\\u003C 30 days) had DVT interventional procedure\n* Subject is participating in another study that may interfere with this study\n* Life expectancy \\\u003C 6 months or chronic non-ambulatory status\n* Known hypercoagulable states that, in the opinion of the Investigator, cannot be medically managed throughout the study period\n* Subject has any condition for which, in the opinion of the Investigator, participation would not be in the best interest of the subject (e.g., contraindication to use of ClotTriever per local approved labeling, compromise the well-being or that could prevent, limit, or confound the protocol-specified assessments)\n* Subject has previously completed or withdrawn from this study\n* Patient unwilling or unable to conduct the follow up visits per protocol","ALL","18 Years",{"count":20,"type":21},300,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study is a prospective, multicenter, randomized controlled trial of an interventional strategy using the ClotTriever System to achieve and maintain vessel patency (ClotTriever Intervention Arm) versus conservative medical management using anticoagulation therapy alone (Conservative Medical Management Arm) in the treatment of subjects with symptomatic unilateral iliofemoral DVT. The study will collect data on demographics, comorbidities, details from the DVT diagnosis and treatment, and clinical outcomes through the 6-month follow up visit.",[27,28,29],"Venous Thromboembolism","Deep Venous Thrombosis","Post-Thrombotic Syndrome",[27,28,29,31,32],"Anticoagulation","Percutaneous Mechanical Thrombectomy","RECRUITING","2026-06-30",{"date":36,"type":37},"2026-07-02","ACTUAL",{"date":39,"type":37},"2023-01-06",{"date":41,"type":21},"2027-01-15",{"name":43,"class":44},"Inari Medical","INDUSTRY",64,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":60,"conditions":61,"keywords":62,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":79},"100433453","phase-2-catheter-related-early-thromboprophylaxis-with-enoxaparin-studies-100433453","NCT04924322","Catheter-Related Early Thromboprophylaxis With Enoxaparin Studies","Age-dependent Heterogeneity in the Efficacy of Prophylaxis With Enoxaparin Against Catheter-associated Thrombosis in Critically Ill Children","CRETE","Inclusion criteria\n\n1. \\>36 weeks corrected gestational to \\\u003C17 years old\n2. \\\u003C24 hours after insertion of an untunneled CVC\n3. CVC inserted in the internal jugular or femoral vein\n\nExclusion criteria\n\n1. Radiologic diagnosis of CADVT in the site of insertion in prior 6 weeks\n2. Currently receiving an antithrombotic agent, e.g., LMWH, UFH, warfarin and aspirin, but not UFH at dose to maintain patency of a vascular catheter\n3. Presence of clinically relevant bleeding, i.e., hemoglobin decreased ≥2 g\u002Fdl in 24 hours, required medical or surgical intervention to restore hemostasis, or in the retroperitoneum, pulmonary, intracranial or central nervous system, in the prior 60 days\n4. Surgery in the prior 7 days\n5. Major trauma in the prior 7 days\n6. Presence of coagulopathy, i.e., INR \\>2.0, aPTT \\>50 seconds or platelet count \\\u003C50 x 10\\^3\u002FmcL\n7. Presence of renal failure, i.e., creatinine clearance \\\u003C30 mL\u002Fmin\u002F1.73 m2\n8. Known hypersensitivity to heparin or pork products\n9. Laboratory confirmed HIT\n10. Current pregnancy or lactation\n11. Presence of an epidural catheter\n12. Limitation of care\n13. Previous enrollment in the CRETE Studies","17 Years",{"count":56,"type":21},258,[58,59],"PHASE2","PHASE3","The goal of the CRETE Studies is to investigate the newly identified age-dependent heterogeneity in the efficacy of enoxaparin in reducing the risk of central venous catheter-associated deep venous thrombosis in critically ill children.",[28],[63,64,65,66,67,68],"child","critical illness","venous thromboembolism","enoxaparin","thrombin generation","bleed","2026-06-04",{"date":71,"type":37},"2026-06-08",{"date":73,"type":37},"2022-05-11",{"date":75,"type":21},"2027-08-31",{"name":77,"class":78},"Yale University","OTHER",22,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":22,"phases":89,"briefSummary":90,"conditions":91,"keywords":92,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},"100623695","using-a-blood-test-and-software-tool-to-guide-treatment-for-venous-thromboembolism-100623695","NCT07399977","Using a Blood Test and Software Tool to Guide Treatment for Venous Thromboembolism","A Nonrandomized Trial Using DNA Liquid Biopsies to Guide Anticoagulation For Patients With Cancer-Associated Thromboembolism","Inclusion Criteria:\n\n* Age ≥ 18 with a history of cancer-associated VTE (objectively confirmed symptomatic or incidental\u002Funsuspected proximal lower-limb DVT, symptomatic pulmonary embolism \\[PE\\] or incidental PE in a segmental or more proximal pulmonary artery) and completion of between 3 and 12 months of anticoagulation with enoxaparin, dalteparin,rivaroxaban, or apixaban without current VTE-related symptoms (imaging to confirm resolution not required).\n\nDiagnosis of DVT requires evidence of one or more filling defects at compression ultrasonography, venography, CT venography, or MR venography involving at least the popliteal or more proximal veins.\n\nDiagnosis of PE requires an intraluminal filling defect in segmental or more proximal arteries.\n\n* Diagnosis of one of the following solid tumors in either advanced (i.e. unresectable) stage or receiving systemic anticancer treatment within six weeks of enrollment (maintenance therapy included):\n\n  * breast cancer regardless of cytotoxic-chemotherapy status\n  * hepatobiliary cancer regardless of cytotoxic-chemotherapy status\n  * prostate cancer regardless of cytotoxic-chemotherapy status\n  * non-small cell lung cancer with cytotoxic-chemotherapy received within 30 days\n  * pancreatic cancer with cytotoxic-chemotherapy received within 30 days\n  * bladder cancer with cytotoxic-chemotherapy received within 30 days\n* Signed and dated informed consent by study participant\u002FLegally Authorized Representative (LAR).\n\nExclusion Criteria:\n\n* Contraindication to ongoing anticoagulation\n* Contraindication to discontinuation of anticoagulation (examples include but not limited to: known antiphospholipid syndrome or factor V leiden, active arterial thrombus, catheter-associated thrombus, on anticoagulation for atrial fibrillation or other non-oncologic reasons)\n* History of major bleeding in the last six months (major bleeding defined as fatal bleeding, and\u002For symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome; bleeding that necessitates acute surgical intervention; bleeding causing a fall in hemoglobin levels of 1.24 mmol\u002FL (2 g\u002FdL or greater) or more; or bleeding leading to a transfusion of 2 U or more of whole blood or red cells).\n* Known diagnosis of disseminated intravascular coagulation (DIC)\n* Suspicion for tumor thrombus on the imaging leading to original diagnosis of VTE\n* Enrolled in hospice care\n* Currently has inferior vena cava (IVC) filter\n* Diagnosis of an active hematologic malignancy",{"count":88,"type":21},259,[24],"The purpose of this study is to find out whether a software tool, ctDNA\u002FVTE (Venous Thromboembolism) risk score model, is an effective way to predict the likelihood of VTE coming back in people who have received anticoagulant treatment.",[27,28],[27,28,93,94],"25-095","Memorial Sloan Kettering Cancer Center","2026-05-04",{"date":97,"type":37},"2026-05-05",{"date":99,"type":37},"2026-01-30",{"date":101,"type":21},"2030-01-30",{"name":94,"class":78},8,{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":111,"sex":17,"minAge":18,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":22,"phases":115,"briefSummary":116,"conditions":117,"keywords":123,"overallStatus":129,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":4},"100614595","bedside-bike-early-mobilization-program-for-inpatients-100614595","NCT07281638","Bedside Bike Early Mobilization Program for Inpatients","BB-STEP","Inclusion Criteria:\n\n* Age 18 years or older\n* Admitted to participating hospital unit within 24 hours or less\n* Expected hospital stay of at least 3 days\n* Able to follow one-step commands\n* Anti-gravity leg strength\n* Informed consent obtained from patient or legally authorized representative\n\nExclusion Criteria:\n\n* Hemodynamic instability requiring vasopressor support with systolic blood pressure \\\u003C90 mmHg\n* Requiring fraction of inspired oxygen (FiO₂) \\>0.6 or positive end-expiratory pressure (PEEP) \\>8 cm H₂O\n* Uncontrolled cardiac arrhythmia\n* Open lower extremity wounds within the pedal arc area\n* Lower limb fracture requiring traction or immobilization\n* Active deep vein thrombosis (DVT) without therapeutic anticoagulation\n* Body mass index (BMI) \\>45 kg\u002Fm² (exceeds device reach limit)\n* Current pregnancy\n* Concurrent enrollment in another interventional clinical trial that would conflict with study procedures or outcomes",true,"110 Years",{"count":114,"type":21},80,[24],"Hospital immobility leads to serious complications including muscle loss, weakness, delirium, pressure ulcers, and blood clots. Despite being medically stable, hospitalized patients spend over 90% of their time in bed due to staffing shortages, fall risks, and limited physical therapy availability. Within one week of admission, patients can lose approximately 2% of thigh muscle mass per day, and nearly half develop clinically significant hospital-acquired weakness.The Bedside Bike is a portable, low-resistance exercise device that clamps securely to hospital beds, allowing patients to perform leg and arm cycling exercises safely without leaving their bed. This study will evaluate whether hospitalized patients at Indiana University Health facilities can feasibly and safely use the Bedside Bike to maintain mobility during their hospital stay.This quality improvement study will enroll 80 adult inpatients expected to stay at least 3 days. All participants will receive the Bedside Bike in addition to usual care (standard physical therapy and medical treatment). The study will measure how often patients use the device, whether it is safe (tracking any device-related problems), and whether it may help improve outcomes such as hospital length of stay, functional mobility scores, discharge to home, and rates of hospital-acquired weakness. Participants will have functional assessments at admission and discharge, use the Bedside Bike throughout their hospitalization (targeting at least 15 minutes daily), and be followed for 60 days after discharge to track readmissions, falls, living arrangements, and mortality.",[118,28,119,120,121,122],"Immobility Syndrome","Delirium","Hospital Acquired Condition","Fall","Mobility Limitation",[124,125,126,127,128],"Immobility Harm","Hospital-Acquired Disability","Falls","Deconditioning","In-bed exercise","NOT_YET_RECRUITING","2026-03-24",{"date":132,"type":37},"2026-03-27",{"date":134,"type":21},"2026-07-05",{"date":136,"type":21},"2026-12-31",{"name":138,"class":78},"Indiana University",{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":146,"enrollmentInfo":147,"targetDuration":4,"studyType":22,"phases":149,"briefSummary":151,"conditions":152,"keywords":4,"overallStatus":129,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":162},"100553445","phase-4-second-line-endovascular-treatment-in-acute-dvt-100553445","NCT06486181","Second Line Endovascular Treatment in Acute DVT","A Randomized Controlled Trial for Second Line Treatment of Acute DVT With Endovascular Interventional Treatments","Inclusion Criteria:\n\n* Patients over 18 years of age\n* Patients who have diagnosis of acute femoropopliteal acute deep venous thrombus\n* Patients eligible for anticoagulation treatment\n\nExclusion Criteria:\n\n* Patients under 18 years of age\n* Patients over 75 years of age\n* Symptoms starting date of more than 14 days\n* Patients who have contraindication for anticoagulation treatment\n* Patients who have high bleeding risk (more than 2 of the following risk factors):\n\n  * Age \\>65 years\n  * Previous bleeding\n  * Cancer\n  * Metastatic cancer\n  * Renal failure\n  * Liver failure\n  * Thrombocytopenia\n  * Previous stroke\n  * Diabetes\n  * Anemia\n  * Antiplatelet therapy\n  * Poor anticoagulant control\n  * Comorbidity and reduced functional capacity\n  * Recent surgery in 30 days\n  * Frequent falls\n* Hemodynamically unstable patients\n* Patients having severe swelling and pain, cyanosis, and absent pulses consistent with compartment syndrome.","75 Years",{"count":148,"type":21},100,[150],"PHASE4","The goal of this study is to fill the paucity of second line endovascular treatment for acute deep venous thrombus (DVT) by using catheter-directed thrombolysis (CDT) and mechanical thrombectomy (MT) as adjunctive second-line treatments for acute DVT patients who show no improvement after an initial anticoagulation trial for one week. The main questions the study aims to answer are:\n\n\\- Are adjunctive use of endovascular interventional treatments as second-line to DVT treatment safe and efficient?\n\nParticipants will be followed with repeat US at 1 week after initial DVT to assess for response to anticoagulation treatment. If there is significant residual thrombus with minimal or no response to treatment, participants will be offered enrollment to the study in the office or inpatient setting. Enrolled participants will be randomized into control or intervention arms with 1:1 ratio. Researchers will compare follow-up Villalta and Marder scores between groups to see whether endovascular interventions are safe and efficient.",[28],"2026-01-26",{"date":155,"type":37},"2026-01-28",{"date":157,"type":21},"2026-04-01",{"date":159,"type":21},"2029-04-30",{"name":161,"class":78},"Rush University Medical Center",1,{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":4,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":17,"minAge":170,"maxAge":4,"enrollmentInfo":171,"targetDuration":4,"studyType":22,"phases":173,"briefSummary":174,"conditions":175,"keywords":179,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":188,"locationsCount":162},"100378717","chips-vte-study-in-hospitalized-patients-to-prevent-hospital-acquired-venous-thromboembolism-100378717","NCT04211181","CHIPs-VTE Study in Hospitalized Patients to Prevent Hospital-Acquired Venous Thromboembolism","Effect on Thromboprophylaxis Among Hospitalized Patients Using a System-wide Multifaceted Quality Improvement Intervention: Rationale and Design for a Multicenter Cluster Randomized Clinical Trial in China","Inclusion Criteria:\n\n1. Aged ≥14 years\n2. Have an expected hospital stay ≥72 hours for medical and\u002For surgical treatment\n3. Written informed consent\n\nExclusion Criteria:\n\n1. Inability to be followed-up at until 3 months after randomization\n2. Have participated in similar trials or are undergoing other clinical trials\n3. Refuse or are unable to give informed consent\n4. VTE identified on CTPA or lower extremity vein ultrasound at or any time before enrollment\n5. Requiring a full dose of anticoagulant treatment (e.g., recent VTE, atrial fibrillation).","14 Years",{"count":172,"type":21},5800,[24],"Although pharmacologic and mechanical methods to prevent VTE are safe, effective, cost-effective, and advocated by authoritative guidelines,many studies continue to demonstrate that these preventive methods are significantly underutilized, especially in China.A number of quality improvements (QI) program have been established in several countries or hospitals.However,no exit effective protocol has been demonstrated well enough or adequate to drive breakthrough levels of improvement. A reliable and practical QI that can support hospitals or physicians in China is warranted.To evaluate the multifaceted quality improvement intervention effect in clinical setting, we will conduct a cluster-randomized clinical trial among China PUlmonary Thromboembolism REgistry Study (CURES) group, aiming to test whether it's applicable to real-world practice in China.\n\nA multicenter, two-arms, open-label clinical trial has been designed to determine whether the system-wide multifaceted intervention could increase the rate of at-risk participants who received prophylaxis (RP) and decrease the incidence of any hospital-associated VTE in 90 days during and after hospital admission. .Selected hospital will be regarded as a cluster and randomized into interventional or control group.In interventional group, eligible hospitalized patients will receive a variety of the multifaceted quality improvement(QI) interventions since admitted in hospital.In control group, patients will receive no more than common recommended care or an existing policy.The primary outcomes are the proportion of appropriate prophylaxis in hospitalized patients and the incidence of HA-VTE in 90 days after hospital admission.",[176,177,27,28,178],"Venous Thromboembolic Disease","Pulmonary Embolism","Quality Improvement",[180,27,181],"Quality improvement","Hospital Associated-VTE","2025-09-11",{"date":184,"type":37},"2025-09-17",{"date":186,"type":37},"2025-08-01",{"date":136,"type":21},{"name":189,"class":78},"China-Japan Friendship Hospital"]